Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Marathon Petroleum Corp (MPC) vs TransMedics Group Inc (TMDX) Price & Performance

Marathon Petroleum CorpTrade
TransMedics Group IncTrade

Price performance (Past 24H)

Key statistics

Marathon Petroleum Corp vs TransMedics Group Inc — how do they compare? Marathon Petroleum Corp trades at $400 (market cap $111.70B), while TransMedics Group Inc trades at $85.89 (market cap $3.06B). The key difference: Marathon Petroleum Corp is far larger — about 36.5× TransMedics Group Inc's market cap, and Marathon Petroleum Corp pays a 1.01% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.

MPCTMDX
Market Cap
$111.70B$3.06B
Sector
EnergyTechnology
52-Week High
$399.44$150.42
52-Week Low
$162.63$61.99
Enterprise Value
$138.23B$3.46B
Dividend Yield
1.01%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Marathon Petroleum Corp

Marathon Petroleum (MPC) trades at $397.77, up 2.28% today and near its 52-week high, with a bullish technical outlook from moving averages and strong momentum. The company has consistently beaten earnings estimates, with Q2 2026 EPS of $17.73 surpassing the $14.27 forecast. Valuation ratios appear attractive with a P/E of 13.79 and P/S of 0.77, while profitability metrics like a 47.9% ROE highlight efficient capital use. Recent news emphasizes refinery investments and benefits from geopolitical energy risks.

The outlook for MPC is positive, driven by robust earnings performance, favorable refining margins, and strong analyst support with 26 buy ratings. Key opportunities include high-return projects and cash flow growth, with 2026 net income projected at $8.6B. Risks involve exposure to oil price volatility, cyclical demand, and rising debt-to-asset ratios, which increased to 42.59% in 2025. Investors should weigh solid fundamentals against sector-specific headwinds.

TransMedics Group Inc

TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.

The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Marathon Petroleum Corp

Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.

Read more on MPC

About TransMedics Group Inc

TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.

Read more on TMDX